AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 3 - (NewsRx.com & NewsRx.net) -- Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than does the existing bacille Calmette-Guerin (BCG) vaccine.
According to a study from Australia and France, "We demonstrate Mycobacterium tuberculosis that is unable to export the complex lipid phthiocerol dimycocerosate has a decreased capacity to replicate in mice and affords sustained protective immunity against M. tuberculosis infection. Protection was significantly better than that provided by the existing vaccine, Mycobacterium bovis bacille Calmette-Guerin (BCG), and this improved protective efficacy was maintained for at least 24 weeks after vaccination."
"Protection afforded by this attenuated strain coincided with a number of factors that were not associated with BCG vaccination: long-term persistence of the strain within the host, sustained and potent induction of antimycobacterial interferon-gamma-secreting cells equal to that induced by virulent M. tuberculosis, and elicitation of T cells recognizing dominant M. tuberculosis antigens absent from BCG," reported Rachel Pinto and collaborators at the Centenary Institute of Cancer Medicine and Cell Biology and University of Sydney in Australia and the ...